Scrotal recurrence of germ cell tumour in a non-violated scrotum

Authors

  • Jenny Li Schulich School of Medicine & Dentistry, Western University, London ON
  • Nicholas Power Division of Urology, London Health Sciences Centre, Western University, London ON

DOI:

https://doi.org/10.5489/cuaj.3505

Abstract

Testicular cancer is the most common cancer diagnosis in males aged 15‒30 years. For over a century, radical inguinal orchiectomy has been the standard of care for initial treatment of testicular cancer. This approach is preferred over trans-scrotal interventions, in an effort to avoid tumour seeding, spermatic cord invasion, and disturbance to lymphatic drainage. Scrotal violation is defined as any trans-scrotal intervention that may impact spread of disease in testicular cancer, including scrotal orchiectomy, fine-needle aspiration, and testicular biopsy. Studies have shown statistically significant differences in local recurrence rates between patients who undergo the standard inguinal surgical approach and cases with scrotal violation.

Over 95% of testicular cancers are curative, often with surgery alone. Recurrence of disease is divided into two categories: local and distant sites. Local recurrence of testicular cancer involves the scrotal and inguinal regions, including superficial inguinal lymph nodes. More commonly, local recurrence is seen in cases of testicular cancer with scrotal violation. We describe a case of local recurrence of testicular cancer in a non-violated scrotum,

Downloads

Download data is not yet available.

Author Biography

Nicholas Power, Division of Urology, London Health Sciences Centre, Western University, London ON

MD

Downloads

Published

2016-11-10

How to Cite

Li, J., & Power, N. (2016). Scrotal recurrence of germ cell tumour in a non-violated scrotum. Canadian Urological Association Journal, 10(11-12), E388–91. https://doi.org/10.5489/cuaj.3505

Issue

Vol. 10 No. 11-12 (2016): CUAJ November

Section

Residents' Room

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.